These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 19423165)

  • 1. Are environmental regulations keeping up with innovation? A case study of the nanotechnology industry.
    Fairbrother A; Fairbrother JR
    Ecotoxicol Environ Saf; 2009 Jul; 72(5):1327-30. PubMed ID: 19423165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential environmental impact of engineered nanomaterials.
    Colvin VL
    Nat Biotechnol; 2003 Oct; 21(10):1166-70. PubMed ID: 14520401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The precautionary principle and international conflict over domestic regulation: mitigating uncertainty and improving adaptive capacity.
    Oye KA
    Water Sci Technol; 2005; 52(6):59-64. PubMed ID: 16304935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hierarchy of environmental health and safety practices in the U.S. nanotechnology workplace.
    Engeman CD; Baumgartner L; Carr BM; Fish AM; Meyerhofer JD; Satterfield TA; Holden PA; Harthorn BH
    J Occup Environ Hyg; 2013; 10(9):487-95. PubMed ID: 23927041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology: the next big thing, or much ado about nothing?
    Maynard AD
    Ann Occup Hyg; 2007 Jan; 51(1):1-12. PubMed ID: 17041243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring asbestos: a recurring public policy challenge.
    Lee RJ; Strohmeier BR; Bunker KL; Van Orden DR
    J Hazard Mater; 2008 May; 153(1-2):1-21. PubMed ID: 18180100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necessity and approach to integrated nanomaterial legislation and governance.
    Wang J; Gerlach JD; Savage N; Cobb GP
    Sci Total Environ; 2013 Jan; 442():56-62. PubMed ID: 23178764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the WTO/TBT enquiry point to monitor tendencies in the regulation of environment, health, and safety issues affecting the chemical industry.
    Pio Borges Menezes R; Maria de Souza Antunes A
    Environ Int; 2005 Apr; 31(3):407-16. PubMed ID: 15734193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of regulating biotechnology-derived animals in Canada: animal health and food safety considerations.
    Kochhar HP; Evans BR
    Theriogenology; 2007 Jan; 67(1):188-97. PubMed ID: 17097725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From cradle-to-grave at the nanoscale: gaps in U.S. regulatory oversight along the nanomaterial life cycle.
    Beaudrie CE; Kandlikar M; Satterfield T
    Environ Sci Technol; 2013 Jun; 47(11):5524-34. PubMed ID: 23668487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure assessment approaches for engineered nanomaterials.
    Abbott LC; Maynard AD
    Risk Anal; 2010 Nov; 30(11):1634-44. PubMed ID: 20626687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A risk management initiative implemented in Canada.
    Lacoursiere JP
    J Hazard Mater; 2006 Mar; 130(3):311-20. PubMed ID: 16125308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensors as tools for quantitation, nanotoxicity and nanomonitoring assessment of engineered nanomaterials.
    Sadik OA; Zhou AL; Kikandi S; Du N; Wang Q; Varner K
    J Environ Monit; 2009 Oct; 11(10):1782-800. PubMed ID: 19809701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomaterial health effects--Part 2: Uncertainties and recommendations for the future.
    Powell MC; Kanarek MS
    WMJ; 2006 May; 105(3):18-23. PubMed ID: 16749320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk management of nanomaterials.
    Gwinn MR; Tran L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(2):130-7. PubMed ID: 20077523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting it right the first time: developing nanotechnology while protecting workers, public health, and the environment.
    Balbus JM; Florini K; Denison RA; Walsh SA
    Ann N Y Acad Sci; 2006 Sep; 1076():331-42. PubMed ID: 17119213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles and practices of health risk assessment under current EU regulations.
    Rudén C
    Regul Toxicol Pharmacol; 2006 Feb; 44(1):14-23. PubMed ID: 16188358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research strategies for safety evaluation of nanomaterials, Part I: evaluating the human health implications of exposure to nanoscale materials.
    Thomas K; Sayre P
    Toxicol Sci; 2005 Oct; 87(2):316-21. PubMed ID: 16049265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnological medical devices and nanopharmaceuticals: the European regulatory framework and research needs.
    Rickerby DG
    J Nanosci Nanotechnol; 2007 Dec; 7(12):4618-25. PubMed ID: 18283854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research strategies for safety evaluation of nanomaterials, part VII: evaluating consumer exposure to nanoscale materials.
    Thomas T; Thomas K; Sadrieh N; Savage N; Adair P; Bronaugh R
    Toxicol Sci; 2006 May; 91(1):14-9. PubMed ID: 16476686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.